Board Change • May 21
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. Independent Director Jakob Have was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • Nov 25
Strategic Partners A/S, Annual General Meeting, Apr 28, 2026 Strategic Partners A/S, Annual General Meeting, Apr 28, 2026, at 10:00 Romance Standard Time. Announcement • Sep 17
Strategic Partners A/S Revises Earnings Guidance for the Fiscal Year 2025 Strategic Partners A/S revised earnings guidance for the fiscal year 2025. Based on the first half of the year the company changes its outlook from previously an operating loss in the range of DKK -3 to -4 million to DKK -2 to -3 million. Announcement • Jan 10
Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP). Stockslatten AB acquired 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025. As part of acquisition, 2,327,058 shares were acquired.
Stockslatten AB completed the acquisition of 11.80% stake in CombiGene AB (publ) (OM:COMBI) from Strategic Partners A/S (CPSE:STRAP) on January 9, 2025. Announcement • Dec 27
Strategic Partners A/S, Annual General Meeting, Mar 26, 2025 Strategic Partners A/S, Annual General Meeting, Mar 26, 2025. New Risk • Sep 30
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€6.71m market cap, or US$7.47m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding). New Risk • Sep 25
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (€5.02m market cap, or US$5.62m). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). New Risk • Mar 30
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€5.68m market cap, or US$6.13m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Board Change • Mar 11
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Director Jakob Have is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Announcement • Feb 22
Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI). Orphazyme A/S (CPSE:ORPHA) acquired an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024. Orphazyme informed CombiGene that they in total have acquired approximately 10% of the outstanding shares in CombiGene, which makes Orphazyme one of the larger shareholders in the Company. Orphazyme A/S (CPSE:ORPHA) completed the acquisition of an additional unknown minority stake in CombiGene AB (publ) (OM:COMBI) on February 21, 2024. Announcement • May 18
Orphazyme A/S Announces Board Changes Orphazyme A/S announced that during the Annual General Meeting on May 17, 2023, Bo Jesper Hansen, John Sommer Schmidt and Anders Fink Vadsholt withdrew their candidacy as members of the Board of Directors. Michael Schlomo Gabriely Hove, Jakob Færch Bendtsen and Jakob Alsted Have were elected as new members of the Board of Directors by the general meeting. Announcement • Sep 26
Orphazyme A/S Revises Earnings Guidance for the Year 2022 Orphazyme A/S revised earnings guidance for the year 2022. The Company has decided to adjust its outlook for 2022, as published on June 7, 2022. The change is driven by the separation of activities into continuing and discontinued operations. The discontinued activities are related to the sale of assets to KemPharm A/S. The continuing business activities are the limited ongoing operational business activities with only two employees. For the full-year 2022, the company anticipates a loss from continuing operations in the range DKK 40 – 45 million and a positive result from discontinued operations relating to the Sale of Assets to KemPharm of DKK 87.4 million (previously operating profit in the range DKK 10 – 30 million). Breakeven Date Change • Mar 01
Forecast to breakeven in 2024 The 3 analysts covering Orphazyme expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr.46.7m in 2024. Average annual earnings growth of 58% is required to achieve expected profit on schedule. Breakeven Date Change • Jan 01
Forecast to breakeven in 2024 The 4 analysts covering Orphazyme expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr.187.8m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule. Executive Departure • Jul 06
Independent Director Martijn Kleijwegt has left the company On the 30th of June, Martijn Kleijwegt's tenure as Independent Director ended after 4.5 years in the role. We don't have any record of a personal shareholding under Martijn's name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years. Executive Departure • Jul 06
Independent Director Remi P. Droller has left the company On the 30th of June, Remi P. Droller's tenure as Independent Director ended after 6.5 years in the role. We don't have any record of a personal shareholding under Remi P.'s name. A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years. Executive Departure • Jul 06
Independent Director Anders Hedegaard has left the company On the 30th of June, Anders Hedegaard's tenure as Independent Director ended after 3.6 years in the role. As of March 2021, Anders still personally held 15.68k shares (€177k worth at the time). A total of 5 executives have left over the last 12 months. The current median tenure of the management team is 4.67 years. Executive Departure • Mar 27
Independent Director has left the company On the 25th of March, Sten Verland's tenure as Independent Director ended after 10.3 years in the role. We don't have any record of a personal shareholding under Sten's name. A total of 2 executives have left over the last 12 months. Is New 90 Day High Low • Jan 14
New 90-day high: €10.56 The company is up 12% from its price of €9.46 on 16 October 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 4.0% over the same period. Is New 90 Day High Low • Dec 15
New 90-day low: €7.41 The company is down 33% from its price of €10.98 on 16 September 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Is New 90 Day High Low • Oct 21
New 90-day low: €8.67 The company is down 37% from its price of €13.76 on 23 July 2020. The German market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Announcement • Sep 30
Orphazyme A/S has completed a Follow-on Equity Offering in the amount of $83.777606 million. Orphazyme A/S has completed a Follow-on Equity Offering in the amount of $83.777606 million.
Security Name: American Depositary Share
Security Type: Depositary Receipt (Common Stock)
Securities Offered: 3,966,146
Price\Range: $11
Discount Per Security: $0.77
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 3,650,000
Price\Range: $11
Discount Per Security: $0.77
Transaction Features: New Market Listing; Sponsor Backed Offering Announcement • Sep 26
Orphazyme A/S Provides Update on Previously Announced Global Offering Orphazyme A/S announced an update on its previously announced global offering. On September 24, 2020, the Company received a filing communication from the U.S. Food and Drug Administration in connection with its new drug application for arimoclomol for the treatment of Niemann-Pick disease Type C. The FDA letter follows acceptance on a Priority Review basis by the FDA of the Company’s NDA for arimoclomol in NPC and the FDA’s establishment of the Prescription Drug User Fee Act target action date of March 17, 2021. The Company’s receipt of the filing communication does not impact the FDA’s acceptance of the Company’s NDA, the target PDUFA action date or the FDA’s Priority Review determination. In accordance with applicable securities laws, the Company intends to amend the registration statement on Form F-1 on file with the U.S. Securities and Exchange Commission on September 25, 2020. The Company has also updated its proposed timing for the global offering referenced in the company announcement no. 51/2020, dated September 21, 2020, and now intends to price the global offering and announce the subscription price on September 28, 2020, subject to market conditions, and to settle the global offering on October 1, 2020. The Company also reported that the book for the global offering is fully covered as of September 24, 2020. The ordinary shares of the Company are currently listed on Nasdaq Copenhagen under the symbol ”ORPHA”. In connection with the global offering, Nasdaq has approved the listing of the American Depositary Shares in the U.S. under the symbol "ORPH". A registration statement on Form F-1 relating to the proposed sale of the Securities has been filed with the SEC but has not yet become effective. The Securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement on Form F-1 becomes effective. The Board has not yet determined whether to complete the global offering. Even if the Board determines to complete the global offering, the global offering may not be consummated. Neither the timing, number of shares, number of ordinary underlying shares of Orphazyme, nor the price of the ADSs and thereby the price of the underlying shares has been finally determined. If consummated, the final price for the ordinary shares and ADSs will be determined following a book-building process. Is New 90 Day High Low • Sep 26
New 90-day low: €9.92 The company is down 18% from its price of €12.14 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Announcement • Sep 22
Orphazyme A/S Elects Carrolee Barlow as Board of Director Orphazyme A/S elected Carrolee Barlow as new member of the Board of Directors, Extraordinary General Meeting held on September 21, 2020. 